BIONEWS
French drugmaker Abivax cleared Phase 3 and a constructive FDA meeting ahead of its drug application filing. Nine months after a roughly $20 billion takeout was priced in, no large pharma buyer has written a check.
A French drugmaker ran the table on its lead ulcerative colitis program. The buyers haven't picked it up.
Abivax reported positive results from both eight-week induction trials of obefazimod, an oral treatment for moderate-to-severe ulcerative colitis, then posted positive maintenance data, then landed a constructive pre-NDA meeting with the FDA. That meeting, the regulatory gate where a company and the agency align on what an upcoming application will contain, is the strongest public signal yet that the asset is filing-ready. Trade-press coverage of the Phase 3 readout and the program's design treated the data as the moment the asset became unmissable.
It hasn't been unmissable enough. As Adam Feuerstein noted in his STAT+ Biotech Scorecard on Wednesday, "we're nine months into a year in which a takeout of Abivax for $20 billion (give or take a few billion) was deemed likely to happen any day." No transaction has been announced. That roughly $20 billion figure was the market's expectation, not a confirmed bid. The gap between the seller's clock and the buyers' clocks is the structural story.
Obefazimod's clock is running faster than the diligence cycle.
The Phase 3 program, the maintenance extension, and the pre-NDA interaction have compressed the seller's timeline. The next inflection point is no longer a clinical event but a regulatory one. Large multinational pharmaceutical buyers run diligence on assets whose next value-creating event is a clinical readout. Once that readout is past, the asset falls into a different diligence lane, one built around commercial, pricing, and competitive modeling, and that lane is slower and more easily deferred. A buyer who could have justified a roughly $20 billion bet on a binary Phase 3 outcome now has to justify it on a multiyear commercial case against an increasingly crowded UC landscape.
Ulcerative colitis is no longer a wide-open market.
The next launch cohort for moderate-to-severe UC is not a vacuum. JAK inhibitors, sphingosine-1-phosphate modulators, and a denser anti-inflammatory pipeline mean the projected peak share obefazimod was being priced against a year ago is no longer the same number. Buyers underwriting a $20 billion check underwrite against peak share, not peak mechanism, and the share math has moved.
Large pharma runs on a portfolio cycle, not a seller's urgency.
Acquirers don't move on the day an asset becomes de-risked. They move when their internal capital cycle creates room: when a prior integration is digested, when capital has been returned, when a budget window opens. Feuerstein is explicit that 2026 biotech M&A is "off the charts." But the buyers active in that market are the same buyers who have spent the year integrating prior transactions and gating new ones. Abivax is de-risked, not overdue.
Cross-border friction is real, and the August version of it is the easy version.
Feuerstein flags and then dismisses "the French don't work in August" as "the most facile explanation I've heard." He's right to. The harder version is the one that doesn't need a calendar: cross-border deals on late-stage European biotech assets carry financing, FX, and antitrust-review friction, and the larger the price tag, the more friction terms out of the negotiation. A roughly $20 billion ticket with European R&D roots and a US filing path is exactly the shape of deal where bankers spend August and September building, not signing.
What would falsify this.
If a buyer signs before obefazimod's NDA is filed, the structural clock-mismatch story collapses and the real mechanism was ordinary late-stage diligence. If no buyer signs by the time the FDA has accepted the filing, the commercial-pricing story becomes the binding constraint and the $20 billion expectation gets repriced. Watch the next IR release, not the next rumor.